Back to Browse Journals » Pharmacogenomics and Personalized Medicine » Volume 4

Sulfation of fulvestrant by human liver cytosols and recombinant SULT1A1 and SULT1E1

Authors Edavana VK, Yu X, Dhakal IB, Williams S, Ning B, Cook IT, Caldwell D, Falany CN, Kadlubar S

Published Date November 2011 Volume 2011:4 Pages 137—145

DOI http://dx.doi.org/10.2147/PGPM.S25418

Published 17 November 2011

Vineetha Koroth Edavana1, Xinfeng Yu1, Ishwori B Dhakal1, Suzanne Williams1, Baitang Ning2, Ian T Cook3, David Caldwell1, Charles N Falany3, Susan Kadlubar1
1
Division of Medical Genetics, College of Medicine, University of Arkansas for Medical Sciences, Little Rock, AR, USA; 2Division of Personalized Nutrition and Medicine, National Center for Toxicological Research, Food and Drug Administration, Jefferson, AR, USA; 3Department of Pharmacology, University of Alabama, Birmingham, AL, USA

Abstract: Fulvestrant (Faslodex™) is a pure antiestrogen that is approved to treat hormone receptor-positive metastatic breast cancer in postmenopausal women. Previous studies have demonstrated that fulvestrant metabolism in humans involves cytochromes P450 and UDP-glucuronosyltransferases (UGTs). To date, fulvestrant sulfation has not been characterized. This study examined fulvestrant sulfation with nine recombinant sulfotransferases and found that only SULT1A1 and SULT1E1 displayed catalytic activity toward this substrate, with Km of 4.2 ± 0.99 and 0.2 ± 0.16 µM, respectively. In vitro assays of 104 human liver cytosols revealed marked individual variability that was highly correlated with β-naphthol sulfation (SULT1A1 diagnostic substrate; r = 0.98, P < 0.0001), but not with 17ß-estradiol sulfation (SULT1E1 diagnostic substrate; r = 0.16, P = 0.10). Fulvestrant sulfation was correlated with both SULT1A1*1/2 genotype (P value = 0.023) and copy number (P < 0.0001). These studies suggest that factors influencing SULT1A1/1E1 tissue expression and/or enzymatic activity could influence the efficacy of fulvestrant therapy.

Keywords: fulvestrant, sulfotransferase, genotype, copy number

Download Article [PDF] View Full Text [HTML] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php

Other articles by this author:

GSTM1 copy number and promoter haplotype as predictors for risk of recurrence and/or second primary tumor in patients with head and neck cancer

Zhang X, Huang M, Wu X, Kadlubar S, Lin J, Yu X, Fan C, Ning B, Kadlubar FF

Pharmacogenomics and Personalized Medicine 2013, 6:9-17

Published Date: 1 March 2013

Copy number variation in sulfotransferase isoform 1A1 (SULT1A1) is significantly associated with enzymatic activity in Japanese subjects

Yu X, Kubota T, Dhakal I, Hasegawa S, Williams S, Ozawa S, Kadlubar S

Pharmacogenomics and Personalized Medicine 2013, 6:19-24

Published Date: 6 March 2013

Lack of correlation between in silico projection of function and quantitative real-time PCR-determined gene expression levels in colon tissue

Penney RB, Lundgreen A, Yao-Borengasser A, Koroth-Edavana V, Williams S, Wolff R, Slattery ML, Kadlubar S

Pharmacogenomics and Personalized Medicine 2013, 6:99-103

Published Date: 9 September 2013

CYP19A1 single nucleotide polymorphism associations with CYP19A1, NFκB1, and IL6 gene expression in human normal colon and normal liver samples

Penney RB, Lundgreen A, Yao-Borengasser A, Edavana VK, Williams S, Dhakal I, Wolff RK, Kadlubar S, Slattery ML

Pharmacogenomics and Personalized Medicine 2014, 7:163-171

Published Date: 14 July 2014

Readers of this article also read:

Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors

Eduardo Pimenta, Suzanne Oparil

Vascular Health and Risk Management 2009, 5:453-463

Published Date: 19 May 2009

Emerging treatments in the management of psoriasis: biological targeting with ustekinumab

Marina Papoutsaki, Antonio Costanzo, Sergio Chimenti

Clinical, Cosmetic and Investigational Dermatology 2009, 2:95-103

Published Date: 22 May 2009

Safety and efficacy of telbivudine for the treatment of chronic hepatitis B

Melissa K Osborn

Therapeutics and Clinical Risk Management 2009, 5:789-798

Published Date: 1 October 2009

Gene expression for HIV-associated dementia and HIV encephalitis in microdissected neurons 1: preliminary analysis

Shapshak P, Duncan R, Duran EM, Farinetti F, Minagar A, Commins D, Rodriguez H, Chiappelli F, Kangueane P, Levine AJ, Singer E, Somboonwit C, Sinnott JT

Neurobehavioral HIV Medicine 2011, 3:53-78

Published Date: 19 July 2011

GSTM1 copy number and promoter haplotype as predictors for risk of recurrence and/or second primary tumor in patients with head and neck cancer

Zhang X, Huang M, Wu X, Kadlubar S, Lin J, Yu X, Fan C, Ning B, Kadlubar FF

Pharmacogenomics and Personalized Medicine 2013, 6:9-17

Published Date: 1 March 2013

Copy number variation in sulfotransferase isoform 1A1 (SULT1A1) is significantly associated with enzymatic activity in Japanese subjects

Yu X, Kubota T, Dhakal I, Hasegawa S, Williams S, Ozawa S, Kadlubar S

Pharmacogenomics and Personalized Medicine 2013, 6:19-24

Published Date: 6 March 2013

The skin landscape in diabetes mellitus. Focus on dermocosmetic management

Piérard GE, Seité S, Hermanns-Lê T, Delvenne P, Scheen A, Piérard-Franchimont C

Clinical, Cosmetic and Investigational Dermatology 2013, 6:127-135

Published Date: 15 May 2013